Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $1.71 billion. The enterprise value is $1.22 billion.
| Market Cap | 1.71B |
| Enterprise Value | 1.22B |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 66.17 million shares outstanding. The number of shares has increased by 36.51% in one year.
| Current Share Class | 66.17M |
| Shares Outstanding | 66.17M |
| Shares Change (YoY) | +36.51% |
| Shares Change (QoQ) | +11.87% |
| Owned by Insiders (%) | 1.84% |
| Owned by Institutions (%) | 76.78% |
| Float | 36.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.64 |
| P/TBV Ratio | 3.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.59, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.59 |
| Quick Ratio | 11.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.01% and return on invested capital (ROIC) is -27.83%.
| Return on Equity (ROE) | -41.01% |
| Return on Assets (ROA) | -26.14% |
| Return on Invested Capital (ROIC) | -27.83% |
| Return on Capital Employed (ROCE) | -43.09% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.80M |
| Employee Count | 103 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $208,000 in taxes.
| Income Tax | 208,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +125.46% |
| 50-Day Moving Average | 26.21 |
| 200-Day Moving Average | 20.47 |
| Relative Strength Index (RSI) | 49.42 |
| Average Volume (20 Days) | 668,185 |
Short Selling Information
The latest short interest is 9.60 million, so 14.50% of the outstanding shares have been sold short.
| Short Interest | 9.60M |
| Short Previous Month | 9.32M |
| Short % of Shares Out | 14.50% |
| Short % of Float | 26.01% |
| Short Ratio (days to cover) | 15.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -201.99M |
| Pretax Income | -185.16M |
| Net Income | -185.36M |
| EBITDA | -201.83M |
| EBIT | -201.99M |
| Earnings Per Share (EPS) | -$3.11 |
Balance Sheet
The company has $497.26 million in cash and $1.16 million in debt, with a net cash position of $496.10 million or $7.50 per share.
| Cash & Cash Equivalents | 497.26M |
| Total Debt | 1.16M |
| Net Cash | 496.10M |
| Net Cash Per Share | $7.50 |
| Equity (Book Value) | 468.77M |
| Book Value Per Share | 7.11 |
| Working Capital | 460.35M |
Cash Flow
In the last 12 months, operating cash flow was -$134.85 million and capital expenditures -$400,000, giving a free cash flow of -$135.25 million.
| Operating Cash Flow | -134.85M |
| Capital Expenditures | -400,000 |
| Depreciation & Amortization | 155,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -135.25M |
| FCF Per Share | -$2.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.51% |
| Shareholder Yield | -36.51% |
| Earnings Yield | -10.83% |
| FCF Yield | -7.90% |
Analyst Forecast
The average price target for BCAX is $33.50, which is 29.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $33.50 |
| Price Target Difference | 29.54% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |